Log In
BCIQ
Print this Print this
 

Sofpironium bromide (BBI-4000)

  Manage Alerts
Collapse Summary General Information
Company Brickell Biotech Inc.
DescriptionTopical soft anticholinergic
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationExcessive sweating
Indication DetailsTreat hyperhidrosis (excessive sweating); Treat primary axillary hyperhidrosis
Regulatory Designation
PartnerKaken Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today